Table 2.
Occurrence and incidence of neuropsychiatric adverse events and study drug adherence, by treatment and cohort, and by smoking-related-disease subcohort: all treated EAGLES participants
| Treatments | Asthma | COPD | Diabetes | CVD | All disease subcohorts a | No smoking-related diseases b |
|---|---|---|---|---|---|---|
| Neuropsychiatric adverse events, N*, n (%) | ||||||
| All treatments | 481 | 411 | 408 | 283 | 1363 | 5970 |
| 19 (4.0) | 16 (3.9) | 17 (4.2) | 7 (2.5) | 48 (3.5) | 208 (3.5) | |
| Varenicline | 129 | 98 | 100 | 73 | 340 | 1505 |
| 2 (1.6) | 2 (2.0) | 4 (4.0) | 1 (1.4) | 9 (2.6) | 53 (3.5) | |
| Bupropion | 101 | 98 | 110 | 73 | 333 | 1494 |
| 6 (5.9) | 7 (7.1) | 4 (3.6) | 3 (4.1) | 16 (4.8) | 55 (3.7) | |
| NRT | 123 | 98 | 95 | 74 | 336 | 1503 |
| 8 (6.5) | 5 (5.1) | 8 (8.4) | 2 (2.7) | 16 (4.8) | 47 (3.1) | |
| Placebo | 128 | 117 | 103 | 63 | 354 | 1468 |
| 3 (2.3) | 2 (1.7) | 1 (1.0) | 1 (1.6) | 7 (2.0) | 53 (3.6) | |
| Study drug exposure, N*, mean days (SD) | ||||||
| All treatments | 481 | 411 | 408 | 283 | 1363 | 5970 |
| 72.3 (24.0) | 72.5 (24.4) | 75.2 (22.4) | 73.4 (24.8) | 73.0 (24.1) | 74.4 (23.1) | |
| Varenicline | 129 | 98 | 100 | 73 | 340 | 1505 |
| 71.6 (24.5) | 71.3 (26.4) | 76.4 (20.4) | 75.2 (23.1) | 72.7 (24.3) | 75.1 (22.6) | |
| Bupropion | 101 | 98 | 110 | 73 | 333 | 1494 |
| 74.4 (21.7) | 74.2 (23.5) | 72.3 (24.9) | 75.4 (22.7) | 72.9 (24.2) | 74.3 (23.3) | |
| NRT | 123 | 98 | 95 | 74 | 336 | 1503 |
| 71.9 (24.5) | 73.0 (24.0) | 77.1 (21.1) | 72.2 (26.1) | 74.0 (23.5) | 73.8 (23.4) | |
| Placebo | 128 | 117 | 103 | 63 | 354 | 1468 |
| 71.8 (25.0) | 71.8 (23.9) | 75.4 (22.6) | 70.3 (27.5) | 72.4 (24.6) | 74.3 (23.2) | |
*
N: population.
a
Participants may appear in multiple smoking-related-disease subcohorts.
b
Participants without asthma, COPD, diabetes, or CVD.
COPD: chronic obstructive pulmonary disease. CVD: cardiovascular disease. NRT: nicotine replacement therapy. SD: standard deviation.